These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 25330558)
21. Use patents, carve-outs, and incentives--a new battle in the drug-patent wars. Rai A N Engl J Med; 2012 Aug; 367(6):491-3. PubMed ID: 22873529 [No Abstract] [Full Text] [Related]
22. Who owns human genes?: Is DNA patentable? Gostin LO JAMA; 2013 Aug; 310(8):791-2. PubMed ID: 23877839 [No Abstract] [Full Text] [Related]
23. From Bilski back to Benson: preemption, inventing around, and the case of genetic diagnostics. Dreyfuss R; Evans JP Stanford Law Rev; 2011 Jun; 63(6):1349-76. PubMed ID: 21774194 [TBL] [Abstract][Full Text] [Related]
24. LabCorp v. Metabolite Laboratories: The Supreme Court listens, but declines to speak. Klein RD; Mahoney MJ J Law Med Ethics; 2008; 36(1):141-9, 4. PubMed ID: 18315767 [TBL] [Abstract][Full Text] [Related]
25. Patenting of genetic material: are the benefits to society being realized? Willison DJ; MacLeod SM CMAJ; 2002 Aug; 167(3):259-62. PubMed ID: 12186174 [No Abstract] [Full Text] [Related]
26. After the Myriad decision: do hurdles remain for diagnostics competition? Waller PR; Young DW MLO Med Lab Obs; 2013 Sep; 45(9):46. PubMed ID: 24147337 [No Abstract] [Full Text] [Related]
27. Biomarker patents for diagnostics: problem or solution? Hopkins MM; Hogarth S Nat Biotechnol; 2012 Jun; 30(6):498-500. PubMed ID: 22678384 [No Abstract] [Full Text] [Related]
28. The future of gene patents and the implications for medicine. Sherkow JS; Greely HT JAMA Intern Med; 2013 Sep; 173(17):1569-70. PubMed ID: 23896757 [No Abstract] [Full Text] [Related]
29. The Supreme Court, process patents, and medical innovation. Kesselheim AS N Engl J Med; 2009 Dec; 361(24):2303-6. PubMed ID: 19923562 [No Abstract] [Full Text] [Related]
33. Isolated DNA patent ban creates muddy waters for biomarkers and natural products. Harrison C Nat Rev Drug Discov; 2013 Aug; 12(8):570-1. PubMed ID: 23903213 [No Abstract] [Full Text] [Related]
34. Gene patents, patenting life and the impact of court rulings on US stem cell patents and research. Matthews KR; Cuchiara ML Regen Med; 2014 Mar; 9(2):191-200. PubMed ID: 24750060 [TBL] [Abstract][Full Text] [Related]
35. Patents. U.S. Supreme Court delves into what is and isn't patentable. Marshall E Science; 2009 Jun; 324(5933):1374. PubMed ID: 19520926 [No Abstract] [Full Text] [Related]
36. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Furrow ME Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462 [No Abstract] [Full Text] [Related]
37. Intellectual property. Supreme Court to review the scope of Monsanto's seed patents. Marshall E Science; 2013 Feb; 339(6120):639. PubMed ID: 23393238 [No Abstract] [Full Text] [Related]
39. [Tasks and expectations for drug design based on pharmacogenomics]. Uyama Y Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):432-5. PubMed ID: 16463462 [No Abstract] [Full Text] [Related]
40. The evolving role of biomarker patents in personalized medicine. Kesselheim AS; Shiu N Clin Pharmacol Ther; 2014 Feb; 95(2):127-9. PubMed ID: 24448456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]